BidaskClub upgraded shares of Mylan (NASDAQ:MYL) from a sell rating to a hold rating in a report issued on Wednesday morning.
MYL has been the topic of a number of other reports. ValuEngine downgraded Mylan from a hold rating to a sell rating in a report on Wednesday, May 2nd. Zacks Investment Research raised Mylan from a sell rating to a hold rating in a report on Tuesday, January 16th. Susquehanna Bancshares reaffirmed a positive rating and set a $55.00 price target (up from $47.00) on shares of Mylan in a report on Thursday, January 25th. Morgan Stanley set a $50.00 price target on Mylan and gave the company a buy rating in a report on Monday, April 9th. Finally, Cantor Fitzgerald set a $41.00 price target on Mylan and gave the company a hold rating in a report on Thursday, March 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the stock. Mylan currently has a consensus rating of Buy and an average target price of $47.02.
Shares of Mylan opened at $39.66 on Wednesday, Marketbeat.com reports. The firm has a market cap of $20.44 billion, a PE ratio of 8.70, a price-to-earnings-growth ratio of 1.29 and a beta of 1.35. The company has a debt-to-equity ratio of 1.03, a quick ratio of 0.65 and a current ratio of 1.06. Mylan has a 1 year low of $29.39 and a 1 year high of $47.82.
In other Mylan news, insider Paul Campbell sold 7,030 shares of the company’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $44.01, for a total value of $309,390.30. Following the completion of the sale, the insider now owns 17,054 shares in the company, valued at $750,546.54. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Rajiv Malik sold 50,000 shares of the company’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $40.91, for a total value of $2,045,500.00. Following the completion of the sale, the president now owns 503,751 shares of the company’s stock, valued at approximately $20,608,453.41. The disclosure for this sale can be found here. In the last three months, insiders sold 269,287 shares of company stock worth $11,034,960. 0.69% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Analyst IMS Investment Management Services Ltd. purchased a new stake in Mylan in the first quarter worth about $117,000. Rational Advisors LLC purchased a new stake in Mylan in the fourth quarter worth about $190,000. Advisor Partners LLC purchased a new stake in Mylan in the fourth quarter worth about $214,000. First Personal Financial Services increased its position in Mylan by 77.1% in the fourth quarter. First Personal Financial Services now owns 4,839 shares of the company’s stock worth $205,000 after buying an additional 2,106 shares in the last quarter. Finally, M Holdings Securities Inc. purchased a new stake in Mylan in the fourth quarter worth about $383,000. Institutional investors and hedge funds own 83.53% of the company’s stock.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.